NCT03840239View on ClinicalTrials.gov

TNT to Increase the Clinical Complete Response Rate for Distal LARC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

December 25, 2018

Primary Completion Date

December 30, 2023

Study Completion Date

June 30, 2027

Conditions
Rectal CancerRectal Cancer Stage IIRectal Cancer Stage IIIChemoradiation
Interventions
DRUG

Capecitabine, Oxaliplatin

Drug: Capecitabine, Oxaliplatin

RADIATION

External beam radiotherapy

External beam radiotherapy to the primary tumor, regional lymph nodes and clinical target volume

PROCEDURE

Surgery

'Local excision' or 'Intersphincter resection' or 'Total mesorectal excision' or other surgeries

OTHER

Watch and wait strategy

Watch and wait strategy recommendation and discussion for cCR patients

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT03840239 - TNT to Increase the Clinical Complete Response Rate for Distal LARC | Biotech Hunter | Biotech Hunter